Bezlotoxumab + Placebo + Antibacterial drug treatment (ABD)
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Clostridium Difficile Infection
Conditions
Clostridium Difficile Infection
Trial Timeline
Mar 27, 2018 → May 12, 2022
NCT ID
NCT03182907About Bezlotoxumab + Placebo + Antibacterial drug treatment (ABD)
Bezlotoxumab + Placebo + Antibacterial drug treatment (ABD) is a phase 3 stage product being developed by Merck for Clostridium Difficile Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT03182907. Target conditions include Clostridium Difficile Infection.
What happened to similar drugs?
9 of 20 similar drugs in Clostridium Difficile Infection were approved
Approved (9) Terminated (5) Active (11)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03182907 | Phase 3 | Completed |
Competing Products
20 competing products in Clostridium Difficile Infection